Biotechnology

A last-minute regulatory filing by Balyasny Asset Management pulls back the curtain on the multi-billion-dollar battle for Spectris, a key health tech enabler.

Abbott launches two new Ensure shakes, using science and tech to frame muscle health as the key to a longer, stronger life. Is protein the new longevity drug?

A regulatory filing shows hedge fund Balyasny's active trading in Avadel Pharma, exposing a merger arbitrage strategy amid a fierce bidding war.

A strategic partnership integrates cutting-edge AI into drug development, promising to slash timelines and costs. Is this the new blueprint for pharma R&D?

A major CRO presents 10 pivotal studies at the world's top blood disease meeting, revealing a strategy built on real-world data and collaborative innovation.

The medtech giant projects robust growth with an ambitious pipeline, but a high-stakes regulatory showdown over a key acquisition could redefine its future.